Open company graph database — free web & API
Login

CICS Corporation

株式会社CICSCancer Intelligence Care Systems, Inc.Alias
Ticker
—
Listed market
—
Country
Japan
Employees (non-consolidated)
—
Related companies
7
§01

Basic information

BASIC
Head office
17th Floor, TOC Ariake West Tower, 3-5-7 Ariake, Koto-ku, Tokyo 135-0063, Japan
Chief executive
Tetsuya Furukawa
Capital
2,222,007,053  (22 100 million)
Employees (non-consolidated)
Employees (consolidated)
Start date
2005-12-14
End date
§02

Websites

1 DOMAINS
§03

Business

11
Sales and leasing of medical devicesAccelerator neutron capture therapy deviceAutomated synthesis device for positron-emitting radionuclide labeled drugsRadiation therapy fixturesManufacturing and sales of research equipmentDevelopment, manufacturing, sales, repair, maintenance, and leasing of medical and research equipmentConsulting services related to the establishment, merger, business succession, and operation of medical corporationsTechnical guidance and treatment support for medical institutions involved in cancer diagnosis and treatmentResearch and development of positron-emitting radionuclide labeled drug synthesis devices, and acquisition, holding, and operation of related intellectual property rightsResearch and development of drugs related to neutron capture therapy, and acquisition, holding, and operation of related intellectual property rightsResearch, development, manufacturing of neutron sources, and acquisition, holding, and operation of related intellectual property rights
§04

Related companies

7 COMPANIES
Company name Group Parent Subsidiary Customer Supplier Alliance Bank Shareholder
放射線医科学研究所
Alliance
New Energy and Industrial Technology Development Organization
Alliance
Stella Pharma Co., Ltd.
Resort Trust Inc.
Sumitomo Heavy Industries, Ltd.
National Cancer Center Japan
High Medical Co., Ltd.
Shareholder
Names without a link are companies not yet registered in OpenBizGraph
§05

Network

NETWORK
Drag to move · click to open
§06

History

11 EVENTS

Established CICS Corporation in Toranomon, Minato-ku, TokyoSources

Support for the establishment of the Medical Corporation KeisokaiSources

Relocated headquarters to Ariake, Koto-ku, Tokyo due to business expansionSources

Obtained license for high-level management medical device sales and leasingSources

Selected for the 2nd Innovation Commercialization Grant Project by New Energy and Industrial Technology Development Organization (NEDO) in FY 2009Sources

Established Osaki Business Office due to business expansionSources

Selected for the Problem-solving Medical Equipment Development Project by the Ministry of Economy, Trade and Industry in FY 2012Sources

Selected for the FY 2012 Innovation Commercialization Venture Support Project by NEDOSources

Launched Aomi Laboratory inside the Tokyo Metropolitan Industrial Technology Research CenterSources

an accelerator-based neutron capture therapy device was installed when the Hospital’s clinical building was completed in 2014.Sources

will commence a Phase I clinical trial of Boron Neutron Capture Therapy for malignant melanoma and angiosarcoma, using the CICS-1 accelerator-based neutron capture therapy device with lithium targets developed by CICS, and the SPM-011 boron compound for use in BNCT developed by STELLA PHARMA, beginning in November 2019.Sources

§07

News

22 ARTICLES

CICS Submits Application for Manufacturing and Marketing Approval of BNCT SystemSources

On April 30, 2026, CICS submitted an application for manufacturing and marketing approval of CICS-1, a neutron irradiation system for accelerator-based boron neutron capture therapy (BNCT). The system was evaluated at the National Cancer Center Hospital and designated as an orphan medical device. Priority review is expected to support earlier availability.

CICS Registers as a Medical Device ManufacturerSources

CICS Co., Ltd. registered as a medical device manufacturer under Article 23-2-3, Paragraph 1 of Japan's Act on Securing Quality, Efficacy and Safety of Products Including Pharmaceuticals and Medical Devices (registration number 14BZ200454). Headquartered in Koto-ku, Tokyo, the company is represented by President Tetsuya Furukawa. CICS says it will contribute to society by making products that support safety and trust in healthcare.

Domestic Phase II BNCT Trial Results Presented at ESMO Congress 2025Sources

CICS Co., Ltd. and Stella Pharma Corporation conducted a domestic Phase II clinical trial of boron neutron capture therapy (BNCT) for angiosarcoma. On October 20, 2025, local time, Dr. Tairo Kashihara of the National Cancer Center Hospital presented the results in a poster session at ESMO Congress 2025 in Germany.

Investigator-Initiated BNCT Study for Recurrent Breast Cancer ConcludesSources

CICS Co., Ltd. supported a specified investigator-initiated clinical study of BNCT for recurrent breast cancer at Edogawa Hospital, operated by the Jinseisha Social Welfare Corporation, by providing technology for its neutron capture therapy system. A notice of completion has been filed, and the study has concluded.

Domestic Phase II BNCT Trial for Angiosarcoma Meets Primary EndpointSources

CICS Co., Ltd. and Stella Pharma Corporation reported that their domestic Phase II clinical trial of boron neutron capture therapy (BNCT) for angiosarcoma met its primary endpoint. The trial was announced on July 28, 2025, and the companies are continuing to assess treatment efficacy.

CICS BNCT System to Be Featured on TV Tokyo ProgramSources

CICS Co., Ltd.'s BNCT system is scheduled to be featured on TV Tokyo's program 'Roundtable Confidential: Encounters with Other Companies.' The broadcast is scheduled for 11:03 a.m. on July 12, 2025, with the theme 'Japan, a Nation with High Cancer Rates: The Front Line of Countermeasures.'

Seeking Participants for a Clinical TrialSources

CICS Co., Ltd. is conducting a clinical trial for thoracic solid tumors and is seeking participants. Interested people should see the attached leaflet. Unauthorized reproduction is prohibited.

90-Day Observation Period Completed in Domestic Phase II Clinical TrialSources

The 90-day observation period for the primary assessment in the domestic Phase II BNCT trial for angiosarcoma conducted by CICS Co., Ltd. and Stella Pharma Corporation has been completed.

Enrollment Completed; Recruitment for Clinical Trial ClosedSources

CICS Co., Ltd. reported that enrollment in its clinical trial for angiosarcoma has been completed and recruitment has ended. Enrollment completion was confirmed on September 27, 2024.

Agreement Signed for BNCT Clinical TrialSources

CICS Co., Ltd., a consolidated subsidiary of Resorttrust, Inc., signed an agreement with the National Cancer Center, Sumitomo Heavy Industries, Ltd., and Stella Pharma Corporation for a Phase I/II basket trial of boron neutron capture therapy (BNCT). The trial is for patients with recurrent thoracic solid malignancies that are unresectable and for whom standard treatment is difficult to provide.

§09

Sources & updates

SOURCES
↑